anpac_logo_full color_stacked.png
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement
05 mars 2021 16h35 HE | Anpac Bio, USA
SAN JOSE, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)
08 févr. 2021 07h00 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection
01 févr. 2021 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...